In this report, we present the clinical progression of a female patient diagnosed with NSCLC and harboring a <i>KIF5B-MET</i> gene fusion.<h4>Case description</h4>The patient initially exhibited partial response to first-line crizotinib treatment, albeit for a short duration and with limited efficacy. Here, KIF5B is linked to non-small cell lung carcinoma.